Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. PODCAST with prof. Thomas Powles about Keynote-426: Pembrolizumab plus axitinib as a first-line
    treatment option for patients with advanced clear cell renal cell carcinoma

2. Durable responses with amivantamab and lazertinib in chemotherapy-naïve patients with EGFR-mutant
    NSCLC who relapsed on osimertinib

3. First-line immunotherapy-based therapy prolongs the survival of patients with advanced oesophageal
   squamous cell carcinoma

4. Trastuzumab plus endocrine therapy is non-inferior to trastuzumab plus chemotherapy in patients with
    metastatic HR-positive/HER2-positive breast cancer

5. Toripalimab plus gemcitabine and cisplatin as novel first-line treatment for recurrent or metastatic
    nasopharyngeal carcinoma